AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...

AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...

The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...

Welcome to the Mite Party. In its latest effort to raise awareness about demodex blepharitis, an eye condition that affects 25 million Americans, Tarsus Pharmaceuticals is throwing a party — a Mite ...

Waking up with some gunk in your eyes is usually nothing to worry about. The scientific name for this crust is rheum, and it forms when oil and other debris collect on your eyelids during sleep. But ...

Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal ...

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...